central and peripheral glp-1 systems independently suppress eating and additively Glucagon-like Peptide-1 and the Central/Peripheral
Description
A Korean study has found that probiotic strain Limosilactobacillus fermentum GB102 could enhance GLP-1 receptor agonist (RA) dulaglutide in obesity treatment. The study details that although GLP-1 RA treatments are effective for weight loss, when discontinued, weight regain is common

We explore the evidence.
GLP-1 and GIP medications such as Mounjaro, Zepbound, Wegovy or Ozempic are changing the way people approach weight management

The drug is just the entry point

Understanding individual risk factors, biomarker patterns, and mitigation strategies can help patients and providers optimize treatment tolerability

GLP-1 medicines don't just change your body
